Decoy Therapeutics Inc. (DCOY) stock
DCOYNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.98−0.08 (-7.56%)
Close on Nov 13, 2026Market cap $638.94KP/E –Yield –
Decoy Therapeutics operating margin
Operating margin is operating income as a percentage of revenue.
Decoy Therapeutics's operating margin for the twelve months ending Mar 31, 2022 was -2997.2%. For fiscal 2021 it was -696.3%, against -148.8% the year before. The highest annual figure on record is -86.3% in fiscal 2018.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | -696.3% | −547.5 |
| FY2020 | Dec 31, 2020 | -148.8% | +89.7 |
| FY2019 | Dec 31, 2019 | -238.5% | −152.2 |
| FY2018 | Dec 31, 2018 | -86.3% | +2638.3 |
| FY2017 | Dec 31, 2017 | -2724.6% | +1221.9 |
| FY2016 | Dec 31, 2016 | -3946.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -980.1% | −861.3 |
| Q2 FY2026 | Jun 30, 2026 | -1155.8% | −1028.2 |
| Q2 FY2021 | Jun 30, 2021 | -545.5% | −392.6 |
| Q1 FY2021 | Mar 31, 2021 | -142.2% | +66.9 |
| Q4 FY2020 | Dec 31, 2020 | -118.8% | +79.5 |
| Q3 FY2020 | Sep 30, 2020 | -127.6% | +302.2 |
| Q2 FY2020 | Jun 30, 2020 | -152.9% | −51.1 |
| Q1 FY2020 | Mar 31, 2020 | -209.2% | +24.6 |
| Q4 FY2019 | Dec 31, 2019 | -198.3% | +1041.1 |
| Q3 FY2019 | Sep 30, 2019 | -429.8% | −362.9 |
| Q2 FY2019 | Jun 30, 2019 | -101.8% | +3606.4 |
| Q1 FY2019 | Mar 31, 2019 | -233.8% | +4404.3 |
| Q4 FY2018 | Dec 31, 2018 | -1239.5% | +1622.0 |
| Q3 FY2018 | Sep 30, 2018 | -66.8% | +2208.2 |
| Q2 FY2018 | Jun 30, 2018 | -3708.2% | −1062.5 |
| Q1 FY2018 | Mar 31, 2018 | -4638.1% | −1197.0 |
| Q4 FY2017 | Dec 31, 2017 | -2861.4% | −190.3 |
| Q3 FY2017 | Sep 30, 2017 | -2275.0% | – |
| Q2 FY2017 | Jun 30, 2017 | -2645.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -3441.1% | – |
| Q4 FY2016 | Dec 31, 2016 | -2671.2% | – |
See a number that looks wrong?